Department of Physiology and Cell Biology, School of Medicine, University of Nevada, Reno, Nevada, USA.
Division of Gastroenterology & Hepatology, Stanford University School of Medicine, Stanford, California, USA.
United European Gastroenterol J. 2023 Oct;11(8):750-766. doi: 10.1002/ueg2.12463. Epub 2023 Sep 18.
BACKGROUND/AIM: Diabetes has substantive co-occurrence with disorders of gut-brain interactions (DGBIs). The pathophysiological and molecular mechanisms linking diabetes and DGBIs are unclear. MicroRNAs (miRNAs) are key regulators of diabetes and gut dysmotility. We investigated whether impaired gut barrier function is regulated by a key miRNA, miR-10b-5p, linking diabetes and gut dysmotility.
We created a new mouse line using the Mb3Cas12a/Mb3Cpf1 endonuclease to delete mir-10b globally. Loss of function studies in the mir-10b knockout (KO) mice were conducted to characterize diabetes, gut dysmotility, and gut barrier dysfunction phenotypes in these mice. Gain of function studies were conducted by injecting these mir-10b KO mice with a miR-10b-5p mimic. Further, we performed miRNA-sequencing analysis from colonic mucosa from mir-10b KO, wild type, and miR-10b-5p mimic injected mice to confirm (1) deficiency of miR-10b-5p in KO mice, and (2) restoration of miR-10b-5p after the mimic injection.
Congenital loss of mir-10b in mice led to the development of hyperglycemia, gut dysmotility, and gut barrier dysfunction. Gut permeability was increased, but expression of the tight junction protein Zonula occludens-1 was reduced in the colon of mir-10b KO mice. Patients with diabetes or constipation- predominant irritable bowel syndrome, a known DGBI that is linked to leaky gut, had significantly reduced miR-10b-5p expression. Injection of a miR-10b-5p mimic in mir-10b KO mice rescued these molecular alterations and phenotypes.
Our study uncovered a potential pathophysiologic mechanism of gut barrier dysfunction that links both the diabetes and gut dysmotility phenotypes in mice lacking miR-10b-5p. Treatment with a miR-10b-5p mimic reversed the leaky gut, diabetic, and gut dysmotility phenotypes, highlighting the translational potential of the miR-10b-5p mimic.
背景/目的:糖尿病与肠道-脑相互作用障碍(DGBI)有实质性的共同发生。将糖尿病与 DGBI 联系起来的病理生理和分子机制尚不清楚。microRNAs(miRNAs)是糖尿病和肠道蠕动障碍的关键调节因子。我们研究了关键 miRNA,miR-10b-5p 是否调节受损的肠道屏障功能,从而将糖尿病与肠道蠕动障碍联系起来。
我们使用 Mb3Cas12a/Mb3Cpf1 内切酶创建了一种新的小鼠品系,以全局删除 mir-10b。在 mir-10b 敲除(KO)小鼠中进行功能丧失研究,以表征这些小鼠的糖尿病、肠道蠕动障碍和肠道屏障功能障碍表型。通过向这些 mir-10b KO 小鼠注射 miR-10b-5p 模拟物进行功能获得研究。此外,我们对来自 colonic 黏膜的 mir-10b KO、野生型和注射了 miR-10b-5p 模拟物的小鼠进行 miRNA 测序分析,以确认 (1) KO 小鼠中 miR-10b-5p 的缺乏,和 (2) 模拟物注射后的 miR-10b-5p 的恢复。
小鼠先天性缺失 mir-10b 导致高血糖、肠道蠕动障碍和肠道屏障功能障碍的发展。mir-10b KO 小鼠的肠道通透性增加,但结肠中的紧密连接蛋白 Zonula occludens-1 的表达减少。患有糖尿病或便秘为主的肠易激综合征(一种已知的与漏肠相关的 DGBI)的患者,其 miR-10b-5p 表达明显降低。在 mir-10b KO 小鼠中注射 miR-10b-5p 模拟物可挽救这些分子改变和表型。
我们的研究揭示了一种潜在的肠道屏障功能障碍的病理生理机制,该机制将缺乏 miR-10b-5p 的小鼠的糖尿病和肠道蠕动障碍表型联系起来。用 miR-10b-5p 模拟物治疗可逆转漏肠、糖尿病和肠道蠕动障碍表型,突出了 miR-10b-5p 模拟物的转化潜力。